Prosecution Insights
Last updated: April 19, 2026

Examiner: O'NEILL, MARISOL ANN

Tech Center 1600 • Art Units: 1633

This examiner grants 47% of resolved cases

Performance Statistics

47.1%
Allow Rate
-12.9% vs TC avg
48
Total Applications
+75.0%
Interview Lift
1312
Avg Prosecution Days
Based on 17 resolved cases, 2023–2026

Rejection Statute Breakdown

3.6%
§101 Eligibility
23.8%
§102 Novelty
42.0%
§103 Obviousness
24.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18011704 ENGINEERED REPRODUCTIVE ISOLATION IN ANIMALS Final Rejection The Regents of the University of California
18006900 CANINE AND FELINE INDUCIBLE EXPRESSION CONSTRUCTS FOR GENE THERAPY APPLICATIONS Non-Final OA The Trustees of the University of Pennsylvania
18028180 IMMORTALIZED KERATINOCYTES, LENTIVIRUS FOR KERATINOCYTE IMMORTALIZATION, AND METHODS OF USE Non-Final OA REGENTS OF THE UNIVERSITY OF MINNESOTA
17797633 METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS Final Rejection ASKBIO INC.
18250996 PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS Non-Final OA CHILDREN'S HOSPITAL MEDICAL CENTER
18501627 COMPOSITION AND METHODS FOR INDUCING MYELOID SUPPRESSIVE CELLS AND USE THEREOF Non-Final OA Fate Therapeutics, Inc.
18351561 THREE-DIMENSIONAL CULTURE SYSTEM FOR GENERATING CARDIAC SPHEROIDS Non-Final OA THE UAB RESEARCH FOUNDATION
17907187 MUSCLE TISSUE PRODUCED BY BIOPRINTING Final Rejection OSAKA UNIVERSITY
18041873 Use of Amylase or Maltose to Treat or Prevent Neurodegeneration Final Rejection St. Jude Children's Research Hospital, Inc.
17759308 METHOD FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS Non-Final OA Koji TANABE
17267699 Expansion of TILs from Cryopreserved Tumor Samples Final Rejection Iovance Biotherapeutics, Inc.
18409015 PREPARATION METHOD AND USE OF HYDROGEL MATERIAL FOR GROWTH OF BLOOD VESSEL ORGANOIDS Non-Final OA Union Hospital Tongji Medical College HUST
17743069 COMPOSITIONS AND METHODS OF REPROGRAMMING T CELLS TO TREAT DISEASE Non-Final OA MedicaMetrix, Inc.
18570823 UMBILICAL CORD BLOOD MONONUCLEAR CELLS AND RED CELL FRACTION IMPROVE NEUROGENESIS AND BEHAVIORAL RECOVERY AFTER HYPOXIA-ISCHEMIC BRAIN DAMAGE Non-Final OA MONONUCLEAR THERAPEUTICS LIMITED
18551317 METHOD FOR PRODUCING CULTURE CELLS REQUIRING A SUPPLY OF FERRIC IRON Non-Final OA Safi Biotherapeutics, Inc.
18271112 MEDIUM FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, METHOD FOR CULTURING AND EXPANDING NEPHRON PROGENITOR CELLS, AND METHOD FOR PRODUCING RENAL ORGANOIDS Non-Final OA Rege Nephro Co., Ltd.
17909113 GENE THERAPY Final Rejection THE UNIVERSITY OF BRISTOL
17924811 DUAL PROMOTER SYSTEMS Non-Final OA Seattle Children's Hospital (dba Seattle Children's Research Institute)
17973358 CELL CULTURE FEEDING DEVICE Final Rejection Regenerative Research Foundation
17926709 VECTORS ENCODING A GLUCOSE-6-PHOSPHATASE (G6PASE-A) FOR GENE THERAPY Final Rejection UNIVERSITE CLAUDE BERNARD LYON 1
18027250 COMPOSITIONS AND METHODS FOR INHIBITING ALPHA-SYNUCLEIN AGGREGATION Non-Final OA Seelos Therapeutics, Inc.
17920711 GENE EDITING OF LRRK2 IN STEM CELLS AND METHOD OF USE OF CELLS DIFFERENTIATED THEREFROM Non-Final OA Aspen Neuroscience, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month